biote (NASDAQ:BTMD) Trading Up 1.2% - Should You Buy?

biote Corp. (NASDAQ:BTMD - Get Free Report) shares traded up 1.2% during mid-day trading on Monday . The stock traded as high as $4.38 and last traded at $4.37. 110,601 shares changed hands during mid-day trading, an increase of 47% from the average session volume of 75,282 shares. The stock had previously closed at $4.32.

biote Trading Down 3.7%

The firm has a market cap of $214.46 million, a PE ratio of 6.43 and a beta of 1.21. The firm has a 50 day moving average price of $4.00 and a 200-day moving average price of $4.12.

biote (NASDAQ:BTMD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $48.99 million for the quarter, compared to analyst estimates of $47.25 million. biote had a negative return on equity of 19.44% and a net margin of 10.93%. Equities analysts forecast that biote Corp. will post 0.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Guines Llc purchased 436,037 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were bought at an average price of $3.26 per share, with a total value of $1,421,480.62. Following the completion of the transaction, the insider directly owned 4,611,071 shares in the company, valued at approximately $15,032,091.46. This represents a 10.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 24.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. boosted its stake in shares of biote by 56.4% in the fourth quarter. Sei Investments Co. now owns 18,321 shares of the company's stock valued at $113,000 after buying an additional 6,605 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in biote by 9.8% in the fourth quarter. Renaissance Technologies LLC now owns 178,994 shares of the company's stock valued at $1,106,000 after purchasing an additional 16,017 shares during the last quarter. Millennium Management LLC bought a new position in biote during the 4th quarter worth approximately $414,000. Squarepoint Ops LLC bought a new stake in shares of biote in the 4th quarter worth approximately $115,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in biote in the 4th quarter valued at approximately $67,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.